Drugs / ZVS101e
ZVS101e
also known as
rAAV2/8-hCYP4V2
Gene therapy (AAV / viral vector) targets CYP4V2 via restoration
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05714904 | Sep 2022 → Mar 2025 | Bietti crystalline corneoretinal dystrophy | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05832684 | Feb 2023 → Jul 2024 overdue | Bietti crystalline corneoretinal dystrophy | Chigenovo Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06743646 | Dec 2024 → Jun 2026 overdue | Bietti crystalline corneoretinal dystrophy | Chigenovo Co., Ltd | Active not recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07653971 | Jul 2026 → Dec 2030 expected | Bietti crystalline corneoretinal dystrophy | Chigenovo Co., Ltd | Not yet recruiting | No outcome recorded |
| — | NCT07307469 | Jul 2026 → Jan 2027 expected | Bietti crystalline corneoretinal dystrophy | Chigenovo Co., Ltd | Enrolling by invitation | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZVS101e | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05714904 ↗ |
| Known as | rAAV2/8-hCYP4V2 | “We conclude that the favorable safety profile and visual improvements identified in this trial encourage the continued development of rAAV2/8-hCYP4V2 (named ZVS101e).” PMID 38653979 ↗ Apr 2024 |
| Action | Restore | “an adeno-associated viral (AAV)-mediated gene-augmentation therapy” PMID 41520174 ↗ Jan 2026 |
| Modality | Gene therapy (AAV / viral vector) | “adeno-associated virus vector expressing CYP4V2” NCT05714904 ↗ |
| Route | Other | “administer the vector by subretinal injection” NCT05714904 ↗ |
| Target | CYP4V2 | “ZVS101e contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human wild type CYP4V2 gene.” NCT05832684 ↗ |